Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars
Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.
AAO Posters Investigate Ranibizumab Biosimilar Impact on Patient Outcomes
Two studies presented at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, demonstrated the impact that a ranibizumab biosimilar (SB11; Byooviz) can have on patient outcomes.
Positive Results for Aflibercept Biosimilars Seen at AAO 2022
Two posters presented at the annual conference of the American Academy of Ophthalmology (AAO) demonstrated positive phase 3 results for proposed biosimilars that reference blockbuster drug, Eylea (aflibercept).
